Formycon to Present FYB202 Biosimilar Data at EADV Congress and UEG Week

Formycon AG will showcase clinical study results for its ustekinumab biosimilar candidate, FYB202, at the European Academy of Dermatology & Venerology (EADV) congress in Amsterdam and the United European Gastroenterology (UEG) Week in Vienna. The data reveal that the FYB202 biosimilar demonstrated similar efficacy to the reference drug, Stelara®, in a Phase III study involving patients with moderate to severe psoriasis.

At the UEG Week, Formycon will present pharmacokinetics data, where FYB202 showed bioequivalence to Stelara® in a Phase I study. These results highlight the potential of FYB202 for treating both psoriasis and chronic inflammatory bowel disease. Regulatory decisions on FYB202 in the US and EU are expected soon.